Home Healthcare Drugs Hemophilia Treatment Market to 2027

Hemophilia Treatment Market to 2027

Publisher: The Insight Partners
Publication Date: February, 2020
Healthcare / Drugs
Pages: 225
Delivery Format: PDF

Global Analysis and Forecasts by Product (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents); Disease (Hemophilia A, Hemophilia B, Hemophilia C); Treatment Type (On-demand, Prophylaxis); Therapy (Replacement Therapy, ITI Therapy, Gene Therapy); End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others), and Geography

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

Hemophilia treatment Market to 2027 – Global Analysis and Forecasts by Product and End User
The global hemophilia treatment is expected to reach US$ 20,507.92 Mn in 2027 from US$ 12,797.36 Mn in 2019. The market is estimated to grow with a CAGR of 6.1% from 2020-2027.
The growth of the hemophilia treatment is primarily attributed to the factors such as increasing prevalence of hemophilia and rise in favorable government initiatives leading to launch of new products in the market. However, high cost related with hemophilia treatment is likely to pose a negative impact on the market growth. On the other hand, growth opportunities in emerging regions are likely to have a positive impact on the growth of the global hemophilia treatment during the forecast period.
Hemophilia is a hereditary bleeding disorder that stops the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. According to data from the National Hemophilia Foundation in 2020, Hemophilia A happens in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is anticipated to be around 20,000 individuals. Moreover, the incidence of hemophilia is not known across the globe but projected at above 400,000 people. Almost 75% of people with hemophilia worldwide are either undiagnosed or receive disparate treatment.
In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7000 in 2000 to around 8500 in 2011 and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies. Thus, increasing prevalence of hemophilia, high cases of under-diagnosed hemophilia cases, and improving healthcare infrastructure will eventually grow the market for hemophilia treatment in the forecast period.
Global hemophilia treatment, based on the product, is segmented into plasma derived coagulation factor concentrates plasma derived coagulation factor concentrates, desmopressin, antifibrinolytic agents. In 2019, the recombinant coagulation factor concentrates held the largest share of the market, by product. Also, recombinant coagulation factor concentrates segment is expected to grow at the fastest rate during the coming years owing to increasing adoption of integrated systems across the globe.
Some of the major primary and secondary sources for Hemostats included in the report are Centers for Disease Control and Prevention (CDC), USFDA, Central Intelligence Agency (CIA), National Clinical Database, and others.

Reasons to buy this report:
• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the hemophilia treatment.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global hemophilia treatment, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Select Plan

1 User License $4,550

Site License License $6,550

Are you looking for a Consultant?

Email Us

Get a Quote

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$4,550

Hemophilia Treatment Market to 2027

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed